12 Health Care Stocks Moving In Thursday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Thursday's pre-market session, several healthcare stocks experienced significant movements. Celularity (CELU) saw a 43.4% increase, while Kronos Bio (KRON) rose by 33.64%. Jin Medical International (ZJYL) and Telesis Bio (TBIO) also saw substantial gains. Conversely, Aravive (ARAV) dropped by 50.5%, AtriCure (ATRC) by 34.16%, and Humana (HUM) by 14.24%, among other decliners.
January 18, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celularity shares rose 43.4% to $0.27, with a market cap of $52.3 million.
The significant pre-market gain for Celularity suggests positive investor sentiment or reaction to recent news, which could lead to continued short-term upward momentum.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Kronos Bio stock increased by 33.64% to $1.43, with a market cap of $83.3 million.
Kronos Bio's substantial pre-market rise indicates strong investor interest, which may result in further short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Telesis Bio stock rose by 20.33% to $0.38, with a market cap of $11.3 million.
Telesis Bio's pre-market increase may attract investor attention, potentially leading to short-term price growth.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
Jin Medical International shares increased by 24.82% to $122.0, with a market cap of $954.9 million.
The notable pre-market gain for Jin Medical International could signal ongoing investor confidence, potentially leading to further short-term gains.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Aravive stock plummeted by 50.5% to $0.05, with a market cap of $4.0 million.
Aravive's significant pre-market decline suggests negative market sentiment or adverse news, likely leading to continued short-term downward pressure.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
NEGATIVE IMPACT
AtriCure shares fell 34.16% to $22.0, with a market cap of $1.0 billion.
The substantial pre-market drop in AtriCure's stock price could reflect investor concerns, potentially leading to further short-term declines.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
NEGATIVE IMPACT
Humana stock declined by 14.24% to $384.0, with a market cap of $47.2 billion.
Humana's notable pre-market decrease may be due to investor concerns or negative developments, which could lead to further short-term depreciation.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90